Leerink Partnrs Lowers Earnings Estimates for Beta Bionics

Beta Bionics, Inc. (NASDAQ:BBNX) – Analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Beta Bionics in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of ($0.51) per share for the quarter, down from their previous estimate of ($0.50). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Several other equities research analysts also recently issued reports on BBNX. Piper Sandler started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set an “overweight” rating and a $26.00 price objective for the company. LADENBURG THALM/SH SH initiated coverage on Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Bank of America began coverage on Beta Bionics in a report on Monday, February 24th. They issued a “buy” rating on the stock. Stifel Nicolaus began coverage on Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $25.00 target price for the company. Finally, Robert W. Baird began coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Stock Down 7.6 %

Shares of BBNX stock opened at $11.71 on Friday. Beta Bionics has a 52 week low of $11.43 and a 52 week high of $24.50. The business’s 50-day moving average is $18.76.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($1.40). The business had revenue of $20.44 million for the quarter, compared to analysts’ expectations of $20.01 million.

Insider Activity at Beta Bionics

In other news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares of the company’s stock, valued at $66,327,183. The trade was a 34.46 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mike Mensinger bought 33,350 shares of the business’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.